UK markets closed
NIKKEI 225
39,667.07 +493.92 (+1.26%) HANG SENG
18,089.93 +17.03 (+0.09%) CRUDE OIL
81.05 +0.22 (+0.27%) GOLD FUTURES
2,311.50 -19.30 (-0.83%) DOW
39,163.28 +51.12 (+0.13%) Bitcoin GBP
48,360.09 -619.28 (-1.26%)
GERN Jan 2026 4.500 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 12:49PM EDT. Market open.
| Previous close | 1.7500 |
| Open | 1.5000 |
| Bid | 1.3000 |
| Ask | 1.6500 |
| Strike | 4.50 |
| Expiry date | 2026-01-16 |
| Day's range | 1.5000 - 1.5000 |
| Contract range | N/A |
| Volume | |
| Open interest | 82 |
Business WireGeron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., June 20, 2024--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 222,660 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
Simply Wall St.Geron Corporation's (NASDAQ:GERN) large institutional owners must be happy as stock continues to impress, up 27% over the past week
Key Insights Institutions' substantial holdings in Geron implies that they have significant influence over the...
ZacksGeron (GERN) Wins FDA Approval for Blood Cancer Drug, Stock Up
Geron's (GERN) shares rise on approval of its first drug. The FDA approves imetelstat for the treatment of adult patients with lower-risk MDS with transfusion-dependent anemia.
© 2024 Yahoo. All rights reserved.